News & Updates

Phototherapy, whether performed at home or in the clinic office, helps improve outcomes in plaque or guttate psoriasis, with the home-based procedure being associated with less financial burden to patients, according to a study.

An interim analysis of PROs from the PSORIATYK SCALP trial shows that treatment with the allosteric TYK2 inhibitor deucravacitinib significantly reduces itch, flaking, and pain specific to the scalp, as well as whole-body itch, vs placebo at week 16 in patients with moderate-to-severe scalp psoriasis, including those with less extensive BSA involvement

Treatment with remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, led to rapid symptom improvement that lasted for 52 weeks in patients with chronic spontaneous urticaria (CSU), according to the pivotal phase III REMIX-1 and -2 studies presented at EADV 2024.

Deucravacitinib, an oral selective inhibitor of tyrosine kinase 2 (TYK2), shows promise in the treatment of lichen planopilaris (LPP), with substantial reductions in disease activity, according to the interim analysis of an open-label, single-arm trial.

Treatment with upadacitinib demonstrated superior efficacy in achieving near-complete skin clearance and little to no itch at 16 weeks compared with dupilumab among adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the LEVEL UP study presented at EADV 2024.

The interleukin-17 blocker bimekizumab delivers sustained clinical benefits lasting up to 2 years for patients with moderate-to-severe hidradenitis suppurativa, as reported in a late-breaking presentation at EADV 2024.